Revealing the molecular portrait of triple negative breast tumors in an understudied population through omics analysis of formalin-fixed and paraffin-embedded tissues

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Vaca Paniagua, Felipe ^a,b,c   Alvarez Gomez, Rosa María ^b   Maldonado Martínez, Hector Aquiles ^b   Pérez Plasencia, Carlos ^b,c   Fragoso Ontiveros, Veronica ^b   Lasa Gonsebatt, Federico ^b   Herrera, Luis Alonso ^d   Cantú, David ^d   Bargallo Rocha, Enrique ^b   Mohar, Alejandro ^b   Durand, Geoffroy ^a   Forey, Nathalie ^a   Voegele, Catherine ^a   Vallée, Maxime ^a   Le Calvez Kelm, Florence ^a   McKay, James ^a   Ardin, Maude ^a   Villar, Stéphanie ^a   Zavadil, Jiri ^a   Olivier, Magali ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; GENOMIC DNA; MEMBRANE PROTEIN; MESSENGER RNA; MICRORNA; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN FOXM1; PROTEIN P53; RETINOBLASTOMA 1 PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ARTICLE; CANCER TISSUE; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; EPIGENETICS; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION PROFILING; GENETIC PROCEDURES; GENETIC VARIABILITY; GENOME SIZE; GENOMICS; HUMAN; HUMAN TISSUE; PROTEIN EXPRESSION; RB1 GENE; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TISSUE FIXATION; TP53 GENE; TRANSCRIPTOMICS; TRIPLE NEGATIVE BREAST CANCER; WHOLE EXOME SEQUENCING; CHEMISTRY; IN VITRO STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; FEMALE; FORMALDEHYDE; HUMANS; IN VITRO TECHNIQUES; MIDDLE AGED; PARAFFIN; RETROSPECTIVE STUDIES; TISSUE FIXATION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84930616615     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126762     Document Type: Article

References (53)

1. Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 2010; 4: 209-229. doi: 10.1016/j.molonc.2010.04.006 PMID: 20537966
2. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013; 18: 123-133. doi: 10.1634/theoncologist.2012-0397 PMID: 23404817
3. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363: 1938-1948. doi: 10.1056/NEJMra1001389 PMID: 21067385
4. Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One. 2013; 8: e55910. doi: 10.1371/journal.pone.0055910 PMID: 23405235
5. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121: 2750-2767. doi: 10.1172/JCI45014 PMID: 21633166
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752. PMID: 10963602
7. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012; 486: 395-399. doi: 10.1038/nature10933 PMID: 22495314
8. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70. doi: 10.1038/nature11412 PMID: 23000897
9. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502. PMID: 16757721
10. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009; 113: 357-370. doi: 10.1007/s10549-008-9926-3 PMID: 18324472
11. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013; 73: 2025-2030. doi: 10.1158/0008-5472.CAN-12-1699 PMID: 23536562
12. Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: Implications for breast cancer screening recommendations. Cancer. 2011; 117: 2747-2753. doi: 10.1002/cncr.25862 PMID: 21656753
13. Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, Blake-Cerda M, Arce C, Motola-Kuba D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011; 117: 3658-3669. doi: 10.1002/cncr.25961 PMID: 21387260
14. Ly M, Antoine M, Andre F, Callard P, Bernaudin JF, Diallo DA. [Breast cancer in Sub-Saharan African women: review]. Bull Cancer. 2011; 98: 797-806. doi: 10.1684/bdc.2011.1392 PMID: 21700549
15. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009; 11: R18. doi: 10.1186/bcr2242 PMID: 19320967
16. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009; 27: 4515-4521. doi: 10.1200/JCO.2008.19.6873 PMID: 19704069
17. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002; 30: 207-210. PMID: 11752295
18. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007; 2: 2366-2382. PMID: 17947979
19. Morris JH, Apeltsin L, Newman AM, Baumbach J, Wittkop T, Su G, et al. clusterMaker: a multi-algorithm clustering plugin for Cytoscape. BMC Bioinformatics. 2011; 12: 436. doi: 10.1186/1471-2105-12-436 PMID: 22070249
20. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011; 27: 431-432. doi: 10.1093/bioinformatics/btq675 PMID: 21149340
21. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LAJ, Kinzler KW. Cancer genome landscapes. Science. 2013; 339: 1546-1558. doi: 10.1126/science.1235122 PMID: 23539594
22. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clin Cancer Res. 2014
23. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499: 214-218. doi: 10.1038/nature12213 PMID: 23770567
24. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013; 494: 366-370. doi: 10.1038/nature11881 PMID: 23389445
25. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013; 45: 977-983. doi: 10.1038/ng.2701 PMID: 23852168
26. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013; 45: 970-976. doi: 10.1038/ng.2702 PMID: 23852170
27. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007; 67: 8433-8438. PMID: 17823410
28. Hermeking H. p53 enters the microRNA world. Cancer Cell. 2007; 12: 414-418. PMID: 17996645
29. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A. 2010; 107: 6334-6339. doi: 10.1073/pnas.0911082107 PMID: 20308559
30. Tian S, Huang S, Wu S, Guo W, Li J, He X. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3' untranslated region. Biochem Biophys Res Commun. 2010; 396: 435-439. doi: 10.1016/j.bbrc.2010.04.112 PMID: 20417621
31. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011; 3: 279-290. doi: 10.1002/emmm.201100136 PMID: 21472990
32. Lu H, Yue J, Meng X, Nickoloff JA, Shen Z. BCCIP regulates homologous recombination by distinct domains and suppresses spontaneous DNA damage. Nucleic Acids Res. 2007; 35: 7160-7170. PMID: 17947333
33. Meng X, Yue J, Liu Z, Shen Z. Abrogation of the transactivation activity of p53 by BCCIP downregulation. J Biol Chem. 2007; 282: 1570-1576. PMID: 17135243
34. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene. 2003; 22: 5784-5791. PMID: 12947386
35. Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013; 12: 104-116. doi: 10.1158/1535-7163.MCT-12-0781 PMID: 23171949
36. Holstege H, Horlings HM, Velds A, Langerod A, Borresen-Dale AL, van de Vijver MJ, et al. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer. 2010; 10: 654. doi: 10.1186/1471-2407-10-654 PMID: 21118481
37. Xu H, Eirew P, Mullaly SC, Aparicio S. The omics of triple-negative breast cancers. Clin Chem. 2014; 60: 122-133. doi: 10.1373/clinchem.2013.207167 PMID: 24298072
38. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009; 15: 907-913. doi: 10.1038/nm.2000 PMID: 19648928
39. Maia AT, Spiteri I, Lee AJ, O'Reilly M, Jones L, Caldas C, et al. Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast. Breast Cancer Res. 2009; 11: R88. doi: 10.1186/bcr2458 PMID: 20003265
40. Schweiger MR, Kerick M, Timmermann B, Albrecht MW, Borodina T, Parkhomchuk D, et al. Genomewide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS One. 2009; 4: e5548. doi: 10.1371/journal.pone.0005548 PMID: 19440246
41. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012; 2: 82-93. doi: 10.1158/2159-8290.CD-11-0184 PMID: 22585170
42. April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, Izzo J, et al. Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One. 2009; 4: e8162. doi: 10.1371/journal.pone.0008162 PMID: 19997620
43. Sfakianos GP, Iversen ES, Whitaker R, Akushevich L, Schildkraut JM, Murphy SK, et al. Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. Gynecol Oncol. 2013; 129: 159-164. doi: 10.1016/j.ygyno.2012.12.030 PMID: 23274563
44. Hall JS, Taylor J, Valentine HR, Irlam JJ, Eustace A, Hoskin PJ, et al. Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer. 2012; 107: 684-694. doi: 10.1038/bjc.2012.294 PMID: 22805332
45. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007; 13: 1668-1674. PMID: 17698639
46. Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest. 2009; 89: 597-606. doi: 10.1038/labinvest.2009.12 PMID: 19290006
47. Goswami RS, Waldron L, Machado J, Cervigne NK, Xu W, Reis PP, et al. Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples. BMC Biotechnol. 2010; 10: 47. doi: 10.1186/1472-6750-10-47 PMID: 20573258
48. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500: 415-421. doi: 10.1038/nature12477 PMID: 23945592
49. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012; 486: 405-409. doi: 10.1038/nature11154 PMID: 22722202
50. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486: 400-404. doi: 10.1038/nature11017 PMID: 22722201
51. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102: 15545-15550. PMID: 16199517
52. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013; 153: 38-55. doi: 10.1016/j.cell.2013.03.008 PMID: 23540689
53. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer. 2013; 13: 497-510. doi: 10.1038/nrc3486 PMID: 23760024